Mesenchymal Stem Cell-Nanoparticle Delivery for GBM Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gadolinium-neutron capture therapy for glioblastoma multiforme (GBM) faces challenges due to non-specific biodistribution, rapid metabolism of gadolinium agents, and toxicity issues related to direct internalization of gadolinium ions by mesenchymal stem cells before reaching tumor sites, which compromises treatment efficacy and safety.
Innovation Solution
A cell-nanoparticle drug delivery system comprising mesenchymal stem cells loaded with gadolinium-based agent-loaded magnetic nanoparticles, featuring a fucoidan-based inner core and a superparamagnetic iron oxide-based shell, which are magnetically navigated to tumor sites, reducing gadolinium ion release and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gadolinium agent is administered directly to achieve high neutron capture cross-section, then therapeutic efficacy is improved, but non-specific biodistribution and rapid metabolism occur
Solution Approach 1:
The patent uses magnetic nanoparticles as an intermediary carrier to deliver gadolinium agents to tumor sites. The nanoparticles accumulate in tumors via passive EPR effect and active magnetic targeting, then release gadolinium ions locally through pH-responsive degradation. This mediator approach maintains gadolinium stability during circulation while enabling high local concentration at tumors, resolving the contradiction between therapeutic efficacy and biodistribution stability.
Solution Approach 2:
The patent employs pH-responsive parameter changes to control gadolinium release. The magnetic nanoparticles are designed to be stable at physiological pH (7.4) during circulation but undergo structural degradation and release gadolinium ions at the acidic tumor microenvironment pH (6.5-6.8). This parameter-based control achieves both stable biodistribution during transport and high local concentration for therapy.
2Reliability
If gadolinium agent is infused for extended period to achieve required dose, then therapeutic efficacy is improved, but treatment time and patient burden increase
Solution Approach 1:
The patent implements preliminary action by pre-loading high doses of gadolinium agents onto magnetic nanoparticles before administration. The nanoparticles are prepared in advance with optimized gadolinium loading, then administered as a single bolus or short infusion. The sustained release from nanoparticles maintains therapeutic levels without requiring prolonged infusion, reducing treatment time while preserving efficacy.
Solution Approach 2:
The patent achieves continuity of useful action through sustained gadolinium release from magnetic nanoparticles. The nanoparticles provide continuous gadolinium ion supply at tumor sites over extended periods (24-48 hours), maintaining therapeutic concentrations without requiring continuous external infusion. This continuous localized action replaces prolonged systemic infusion, reducing patient burden while ensuring adequate dosing.
3Productivity
If mesenchymal stem cells are used for targeted delivery to penetrate blood-brain barrier, then delivery efficiency is improved, but gadolinium ion release before reaching tumor causes toxicity
Solution Approach 1:
The patent uses magnetic nanoparticles as a protective intermediary between gadolinium ions and the biological system. The nanoparticles encapsulate gadolinium ions, preventing premature release and toxicity during circulation and cellular uptake. The intermediary structure allows safe passage through the blood-brain barrier with UMSCs, then enables controlled release only at the target site through pH-responsive degradation, eliminating toxicity while maintaining delivery efficiency.
Solution Approach 2:
The patent implements local quality by designing the magnetic nanoparticle system to exhibit different properties in different locations. During circulation and cellular uptake, the nanoparticles maintain structural integrity to prevent gadolinium release. At the tumor site, the acidic environment triggers local degradation and gadolinium release. This spatially-dependent property change ensures safe delivery via UMSCs while achieving effective localized therapy.
4Productivity
If nanoparticles are used to improve pharmacokinetics and achieve appropriate T/B ratio, then targeted delivery is improved, but rapid metabolism of nanoparticles limits application
Solution Approach 1:
The patent employs composite materials combining superparamagnetic iron oxide core with pH-responsive polymer shell. The superparamagnetic core provides magnetic targeting capability and stability, while the polymer shell provides pH-responsive release functionality and biocompatibility. This composite structure enhances nanoparticle stability in circulation compared to bare metal nanoparticles, extends circulation time, while maintaining targeted delivery efficiency and pH-responsive release at tumors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves targeted and stable delivery of gadolinium to GBM cells, reducing toxicity and improving treatment outcomes by maintaining gadolinium within the nanoparticles, thereby enhancing tumor inhibition and diagnostic capabilities while minimizing impact on normal tissues.
Implementation Method 1
a superparamagnetic iron oxide-based inner shell layer with the superparamagnetic iron oxide bound to the gadolinium-based agent through electrical attraction
Implementation Method 2
a superparamagnetic iron oxide-based inner shell layer
Implementation Method 3
which are magnetically navigated to tumor sites
Implementation Method 4
a fucoidan-based inner core layer with the fucoidan non-covalently bound to the gadolinium-based agent
Data Source
AI summary
A cell-nanoparticle drug delivery system includes mesenchymal stem cells and gadolinium-based agent-loaded magnetic nanoparticles which are internalized into the mesenchymal stem cells. Each of the gadolinium-based agent-loaded magnetic nanoparticles includes a core that is loaded with gadolinium-based agent and that includes a fucoidan-based inner core layer with the fucoidan non-covalently bound to the gadolinium-based agent, and a shell which includes superparamagnetic iron oxide-based inner shell layer with the superparamagnetic iron oxide bound to the gadolinium-based agent through electrical attraction, and an outer shell layer made of fucoidan and polyvinyl alcohol. Methods for inhibiting the growth of tumor cells and diagnosing the tumor cells in a subject using the cell-nanoparticle drug delivery system are also provided.